Wuxi Biologics (Cayman), Inc. is an investment holding company, which provides end-to-end solutions and services for biologics discovery, development, and manufacturing services and manufacturing of biologics products. The company is headquartered in Wuxi, Jiangsu and currently employs 12,552 full-time employees. The company went IPO on 2017-06-13. The firm mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The firm mainly conducts its business in the domestic and overseas markets.
Follow-Up Questions
WuXi Biologics (Cayman) Inc의 CEO는 누구입니까?
Dr. Zhisheng Chen은 2014부터 회사에 합류한 WuXi Biologics (Cayman) Inc의 Chief Executive Officer입니다.
WXXWY 주식의 가격 성능은 어떻습니까?
WXXWY의 현재 가격은 $10이며, 전 거래일에 decreased 0% 하였습니다.
WuXi Biologics (Cayman) Inc의 주요 사업 주제나 업종은 무엇입니까?
WuXi Biologics (Cayman) Inc은 Life Sciences Tools & Services 업종에 속하며, 해당 부문은 Health Care입니다
WuXi Biologics (Cayman) Inc의 시가총액은 얼마입니까?
WuXi Biologics (Cayman) Inc의 현재 시가총액은 $20.3B입니다
WuXi Biologics (Cayman) Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 27명의 분석가가 WuXi Biologics (Cayman) Inc에 대한 분석 평가를 실시했으며, 이는 9명의 강력한 매수, 17명의 매수, 6명의 보유, 0명의 매도, 그리고 9명의 강력한 매도를 포함합니다
